Third Rock puts up $45M for a voyage into gene therapy

Damian Garde Third Rock Ventures has cut the ribbon on its latest startup, pledging $ 45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising ...

J&J Innovation settles into a fast-paced global swirl of dealmaking

John Carroll Over the last 6 months or so, Johnson & Johnson's ($ JNJ) big new innovation initiative has been bringing together deal teams in key R&D hot spots around the ...

PDL injects $70M into Durata; Vivus to cut 20 staffers; FDA outlines proper use of Iclusig

John Carroll FierceBiotech News

AstraZeneca, Amgen Crohn’s drug runs into PhII ‘logistical’ snafu

John Carroll One of the programs involved in AstraZeneca's $ 50 million bid to collaborate with Amgen on the development of a slate of biologics has run into a snafu of some sort. ...

Heart drug developer Trevena jumps into biotech IPO game with $86M pitch

John Carroll The King of Prussia, PA-based biotech says it was the first developer to get into the clinic with a GPCR biased ligand, a program which was inspired in part by scientific ...

Drugmakers shelled out $25K to get into painkiller-approval summit

Tracy Staton The academics who ran the meeting, designed to gather information for developing agency guidelines for drug development, took a hard-sell approach, the em>Post reports, ...

Japan authorities digging deeper into Novartis’ use of flawed Diovan study

Eric Palmer Swiss drugmaker Novartis has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbuster Diovan as a statistician without ...

AbbVie jumps into $405M CF deal with Galapagos

Tracy Staton AbbVie has inked a $ 405 million deal with Belgium's Galapagos to target genetic mutations in patients with cystic fibrosis. FiercePharma News

J&J trying to drag Boehringer into arbitration over Doxil production lapses

Eric Palmer Many drugmakers had supplies interrupted when Boehringer Ingelheim closed its Bedford, OH plant in 2011 because of serious quality issues, but it was a shortage of Johnson ...

Bayer and Broad Institute Dive into Cancer Treatment Options

mia.burns By Mia Burns (mia.burns@ubm.com) Bayer HealthCare executives have announced a strategic alliance with the Broad Institute in Cambridge, Mass. for oncogenomics and drug discovery. ...

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

Ryan McBride Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential ...

Teva gives up on turning Nuvigil into an antidepressant

Tracy Staton The drug, originally approved to treat sleep apnea, had failed another Phase III trial. FiercePharma News
Page 4 of 7« First...23456...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS